-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, R6pLXsMZCMkmrrtNT1tbd2dvSSKPy2oaCATErqPDqpDci5oFWz82L1Uo2nHHufR4 +9R0qGeL12uIoSe/E85pMQ== 0001127602-10-007297.txt : 20100303 0001127602-10-007297.hdr.sgml : 20100303 20100303191026 ACCESSION NUMBER: 0001127602-10-007297 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100301 FILED AS OF DATE: 20100303 DATE AS OF CHANGE: 20100303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GODDARD COLIN CENTRAL INDEX KEY: 0001225199 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 10655022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 41 PINELAWN ROAD CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-03-01 0000729922 OSI PHARMACEUTICALS INC OSIP 0001225199 GODDARD COLIN C/O OSI PHARMACEUTICALS, INC. 41 PINELAWN ROAD MELVILLE NY 11747 1 1 Chief Executive Officer Common Stock 2010-03-01 4 M 0 66000 23.25 A 224265 D Common Stock 2010-03-01 4 S 0 66000 55.17 D 158265 D Stock Option (Right to Buy) 23.25 2010-03-01 4 M 0 66000 0 D 2001-06-21 2010-06-21 Common Stock 66000 34000 D Transaction made pursuant to a 10b5-1 trading plan adopted November 7, 2009. Transaction occured upon exercise of options due to expire on June 21, 2010. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $55.11 to $55.30 per share. The Reporting Person will provide, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. One third of the stock options became exercisable on 6/21/2001 and the remainder vested ratably on a monthly basis over the succeeding 24 months. Includes only options with the same termination date. /s/ Pierre Legault, attorney-in-fact for Dr. Goddard 2010-03-03 -----END PRIVACY-ENHANCED MESSAGE-----